title: A texture analysis approach to quantify ventilation changes in hyperpolarised ³He MRI of the rat lung in an asthma model.
abstract: In preclinical research, allergic asthma is investigated in rats sensitised with the antigen ovalbumin (OVA), followed by a challenge with aerosolised OVA to induce an inflammatory reaction of the lower airways. This causes diffuse, nonfocal ventilation defects that lead to heterogeneously distributed signal intensities in hyperpolarised (HP) (3)He MR images, which are difficult to assess directly by diagnostic grading or volumetry. Texture analysis can characterise these changes and does not require segmentation of the lung structures prior to the analysis. The aim of this work was to evaluate a texture analysis approach to quantify changes in lung ventilation in HP (3)He MRI of OVA-challenged rats. OVA-challenged animals were treated with two different compound doses to evaluate the sensitivity of the texture analysis. Four groups were investigated using HP (3)He MRI at 4.7 T: controls, vehicle-treated, and low- and high-dose budesonide-treated rats. In addition, broncho-alveolar lavage was performed and the eosinophil cell count was used as a biological reference marker. First-order texture, geometrical features and features based on second-order statistics using run-length and grey-level co-occurrence matrices were calculated. In addition, wavelet transforms were applied to compute first-order statistics on multiple scales. The texture analysis was able to show significant differences between the control and untreated vehicle groups as well as between the vehicle and treatment groups. This is in agreement with the findings of the eosinophil cell counts, which were used as a marker for the severity of inflammation. However, not all features used in the different texture analysis methods could differentiate between the treatment groups. In conclusion, texture analysis can be used to quantify changes in lung ventilation as measured with HP (3)He MRI after therapeutic intervention with budesonide.
authors: DECS Imaging&Antibodies, AstraZeneca R&D, Mölndal, Sweden. frank.risse@astrazeneca.com
authors: Frank
authors: F
authors: Risse
authors: Jelena
authors: J
authors: Pesic
authors: Simon
authors: S
authors: Young
authors: Lars E
authors: LE
authors: Olsson
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001249:Asthma / Q000188:drug therapy / Q000503:physiopathology*; D019819:Budesonide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D004804:Eosinophils / Q000187:drug effects / Q000473:pathology; D007091:Image Processing, Computer-Assisted / Q000379:methods*; D016014:Linear Models; D008168:Lung / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D051381:Rats; D011914:Rats, Inbred BN; D012119:Respiration / Q000187:drug effects
chemical_list: D019819:Budesonide